2023
Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.Peer-Reviewed Original Research
2013
Chemoimmunotherapy and Withdrawal of Immunosupression for Monomorphic Posttransplant Lymphoproliferative Disorders
Podoltsev N, Zhang B, Yao X, Bustillo I, Deng Y, Cooper DL. Chemoimmunotherapy and Withdrawal of Immunosupression for Monomorphic Posttransplant Lymphoproliferative Disorders. Clinical Lymphoma Myeloma & Leukemia 2013, 13: 716-720. PMID: 24035715, PMCID: PMC3846604, DOI: 10.1016/j.clml.2013.07.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFemaleGraft RejectionHumansImmunosuppression TherapyImmunotherapyLymphoproliferative DisordersMaleMiddle AgedOrgan TransplantationPrednisoneRituximabTreatment OutcomeVincristineWithholding TreatmentYoung AdultConceptsReduction of immunosuppressionMonomorphic PTLDMedian progression-free survivalMonomorphic posttransplant lymphoproliferative disorderGraft rejection ratePosttransplant lymphoproliferative disorderTreatment-related mortalityProgression-free survivalMulti-institutional settingGraft lossMedian OSComplete responseLymphoproliferative disordersCurrent guidelinesDisease progressionAggressive typePatientsChemoimmunotherapyPTLDComplete withdrawalImmunosuppressionCombination programStepwise approachWithdrawalExcellent results